[logo] HealthTree Foundation
search person

A study for myeloma patients over 65 wanting an aggressive approach that includes transplant

Posted: Feb 05, 2014
A study for myeloma patients over 65 wanting an aggressive approach that includes transplant image

For patients over 65 and in good health, this is a study to determine if a stem cell transplant combined with maintenance therapy is a better option than non-transplant chemotherapy approaches and if it will provide older patients longer remission rates, more time without symptoms, toxicity and therapy, and an improved quality of life. Although several groups have confirmed the feasibility of autologous transplantation in myeloma patients over 65 years of age, the literature related to autotransplantation in this age group remains scarce. Most of the literature related to myeloma treatment in patients over 65 years of age involves non-transplant chemotherapy regimens, so this study will compare the autologous transplant with maintenance therapy compared to non-transplant treatment options for that age group. Study Phase: Phase II Location: University of Iowa For More Information contact Annick Tricot at annick-tricot@uiowa.edu

For patients over 65 and in good health, this is a study to determine if a stem cell transplant combined with maintenance therapy is a better option than non-transplant chemotherapy approaches and if it will provide older patients longer remission rates, more time without symptoms, toxicity and therapy, and an improved quality of life. Although several groups have confirmed the feasibility of autologous transplantation in myeloma patients over 65 years of age, the literature related to autotransplantation in this age group remains scarce. Most of the literature related to myeloma treatment in patients over 65 years of age involves non-transplant chemotherapy regimens, so this study will compare the autologous transplant with maintenance therapy compared to non-transplant treatment options for that age group. Study Phase: Phase II Location: University of Iowa For More Information contact Annick Tricot at annick-tricot@uiowa.edu

The author Jennifer Ahlstrom

about the author
Jennifer Ahlstrom

Myeloma survivor, patient advocate, wife, mom of 6. Believer that patients can contribute to cures by joining HealthTree Cure Hub and joining clinical research. Founder and CEO of HealthTree Foundation. 

Thanks to our sponsors:
Sanofi logo
Adaptive logo
Pfizer logo
GSK logo
newsletter icon

Get the Latest Multiple Myeloma Updates, Delivered to You.

By subscribing to the HealthTree newsletter, you'll receive the latest research, treatment updates, and expert insights to help you navigate your health.